Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with pemetrexed and platinum-based chemotherapy within its marketing authorisation for untreated unresectable advanced malignant pleural mesothelioma.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 4044

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
17 January 2024 - 14 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4044
17 January 2024 - 14 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4044
17 January 2024 In progress. Scoping commencing

For further information on our processes and methods, please see our CHTE processes and methods manual